Abstract
The aim of the research. To assess the role of a-1-3-defensins (HNP1-3) and H. pylori in development of chronic gastroduodenitis (CGD) in children; to study the level of a-1-3-defensin (HNP 1-3) dynamics in children with H. pylori after standard eradication therapy. Material and methods. We examined 102 children aged 8 to 14, including 70 patients with chronic gastroduodenitis in the exacerbation phase. A total of 32 children belonged to health groups I-IIa. All patients underwent FEGD with targeted gastric mucosal biopsy and subsequent morphological assessment of gastro-biopsy specimens. Diagnosis of H. pylori was carried out using bacterioscopy and PCR of gastro-biopsy specimens. The level of a-1-3-defensins in blood serum was measured via ELISA. Results. A significant increase in the level of α-defensins in patients with helicobacter pylori-associated gastritis in comparison with both healthy children (p <0.005) and patients with chronic gastritis not associated with the microorganism (p = 0.004) has been shown. Therewith, it should be noted that among patients with helicobacteriosis, the concentration of α1-3-defensins was of higher statistical significance in patients with severe gastric mucosal inflammation (p = 0.0004). Conclusion. The significant role of α-1-3-defensin in development of CHD in children, including the H. pylori-associated variant, has been determined. In addition, HNP1-3 can be used as a predictor of the severity of gastric mucosal lesions in H. pylori infection, which is necessary for identification of the risk groups of children with severe forms of chronic gastritis.